India’s pet-care industry has spent years as a scattered mix of neighbourhood chemists, unbranded feed shops and the occasional standalone vet clinic, with almost no organised retail chain to speak of. That is starting to change as urban pet ownership rises and owners increasingly treat animals as family members deserving proper healthcare rather than an afterthought. For a company already selling into veterinary pharmaceuticals, buying into an established retail brand is one of the more direct ways to get closer to that shift.
Shares of Fredun Pharmaceuticals Ltd. closed at Rs. 1,392.40, up 3.28 percent from previous close of Rs. 1,348.20. The stock opened at Rs. 1,325.00, reaching an intraday high of Rs. 1,409.90 and low of Rs. 1,325.00. The company currently has a market capitalization of Rs. 2,320 crores.
What’s the News?
With a 26% stake, valued at Rs 300 crore, in the pet-care retailer, Goodman Vetcare Private Limited, Fredun Pharmaceuticals Limited has updated exchanges. Goodman, which describes itself as one of India’s longest-standing dedicated pet pharmacies, is now present in three locations–one 24×7 flagship store in Parel and two others in Mumbai and Navi Mumbai–and its revenue has increased by about 30% each year since 1989, up to now, without any institutional funding.
The two companies are claiming the agreement will bring together Goodman’s retail connections and knowledge of the categories, with Fredun’s manufacturing, healthcare and business-development skills, and that it has an outright goal of making Goodman India’s biggest retail chain of pet-care outlets within five years. The strategy involves the opening of at least eight additional stores in three cities, developing a warehouse to aid the expansion and new stores are expected to be opening for the first time outside Maharashtra by the end of 2027.
Financial & Business Analysis
Looking at the quarterly results of Fredun Pharmaceuticals Ltd., the company’s consolidated revenue increased by 90.40 percent YoY, from Rs. 119.85 crore in Q1 FY26 to Rs. 228.24 crore in Q1 FY27, and increased by 7.13 percent QoQ from Rs. 213.05 crore in Q4 FY26.
In Q1 FY27 Fredun Pharmaceuticals Ltd.’s consolidated net profit increased by 94.23 percent YoY, reaching Rs. 13.13 crore compared to Rs. 6.76 crore during the same period last year. As compared to Q4 FY26, the net profit has increased by 21.80 percent, from Rs. 10.78 crore. The basic earnings per share stood at Rs. 23.82 as against Rs. 14.33 recorded in the same quarter in the previous year, FY2026.
Fredun’s existing business spans human pharmaceuticals such as antihypertensives, antidiabetics and antiretrovirals alongside nutraceuticals, cosmeceuticals and animal healthcare products, sold mostly through manufacturing and export channels into Africa, Southeast Asia, the CIS and Latin America. What it has lacked is a direct, branded consumer-facing retail presence, particularly in the pet-care segment where it already makes products but doesn’t control how they reach the end customer.
In place of a traditional order book, Goodman’s own expansion targets function as the forward pipeline here: the brand is aiming for around Rs 40 crore in revenue by FY27, Rs 56 crore by FY28 and roughly Rs 100 crore by FY31, with new stores expected to reach breakeven within three to four months based on its recent openings. For Fredun, owning a quarter of that growth curve gives it a retail foothold and distribution muscle it didn’t have before, while for Goodman it brings in a manufacturing-savvy partner that can help it scale operations, supply chain and quality systems as it moves from a single-city family business into a multi-city retail chain.
Industry Overview
The timing is right with the real momentum in India’s pet-care economy. The market is estimated to be valued at approximately USD 2.40 billion in 2026 and is expected to expand at an average rate of approximately 15.6% annually, to reach approximately USD 8.38 billion by 2034, due to growing pet population, premiumisation and the slow transition from unorganized retailers to organized retailers and veterinary care.
Specifically, the veterinary services portion of the market, which is the most direct, was estimated at about USD 4.36 billion in 2025 and is expected to grow close to 8% annually through 2034 due to trends of higher disposable income, having pets considered family size and more people using dedicated pet health and wellness products. In that context it’s a pretty old brand with a positive unit economics and a substantial growth story, which is a pretty uncommon combination to get the opportunity to access early.
Company Overview
Fredun Pharmaceuticals Limited is a healthcare and pharmaceuticals company with a diverse product portfolio that includes antihypertensives, antidiabetics, antiretroviral drugs, narcotics, dietary and herbal supplements, cosmeceuticals and animal healthcare products, marketed mainly for export to Africa, Southeast Asia, the CIS and Latin America. This makes Fredun a manufacturer and a retail stake holder in India’s growing pet care ecosystem. The stake in Goodman Vetcare is the first time the diversified healthcare footprint has extended into organized, branded retail.